{
  "id": 19211143,
  "title": "SCYNEXIS at guggenheim healthcare conference: dual-pipeline push",
  "url": "https://urgent.news/2026/11/09/scynexis-at-guggenheim-healthcare-conference-dual-pipeline-push",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T20:13:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/scynexis-at-guggenheim-healthcare-conference-dualpipeline-push-93CH-5013099"
  },
  "original_language": "en",
  "account": "On Monday, November 9th, 2026, SCYNEXIS held its 3rd Annual Guggenheim Healthcare Innovation Conference to reveal its new two-pronged strategy targeting rare kidney disease and invasive fungal infections. Chief Executive David Angulo explained the company has shifted from being a singular antifungal-focused entity to one offering therapies in two separate areas: Autosomal Dominant Polycystic Kidney Disease (ADPKD) and invasive fungal infections. The CEO emphasized that this transformation is a response to the substantial unmet needs that currently lack viable treatment options, particularly in diseases with limited therapeutic options.\n\nSCYNEXIS is currently investing in two primary assets: SCY-770 for ADPKD and SCY-247 for invasive fungal disease, while also maintaining a third asset, BREXAFEMME, under GSK’s relaunch efforts. As of September 2024, the company had $63.2 million in cash on hand, which is expected to last until at least 2029, providing sufficient time to finalize the phase II study for SCY-770 and support its next clinical steps.\n\nThe $63.2 million cash balance is a critical factor for SCYNEXIS’s future plans. This amount will support the company through the phase II study for SCY-770, as well as allow BARDA funding to cover a significant portion of the SCY-247 program. BARDA has committed up to $214 million through various funding options, of which $18.5 million has already been secured, with additional funding contingent upon reaching specific development milestones. Importantly, this funding is non-dilutive, meaning it does not require issuing new shares to the company.\n\nSCY-770, the lead candidate for ADPKD, is progressing towards a phase II study slated for the end of 2024. The company anticipates interim data by Q4 2027. SCY-770 is an AMPK activator, a novel mechanism that could address the disease at a critical point in its biology. Phase I trials have shown that the drug is well tolerated, even at higher doses than previously tested, allowing SCYNEXIS to generate pharmacokinetic models that will guide the phase II dose selection process.\n\nSCY-247, the invasive fungal disease candidate, has completed phase I work in both oral and intravenous formulations, a unique position for systemic antifungals. The company believes that this dual-program approach will allow it to capitalize on large unmet needs in diseases where current treatment options remain limited. ADPKD is a genetic kidney disease with few approved therapies, while invasive fungal infections pose a significant concern for patients with compromised immune systems. Additionally, SCYNEXIS sees potential in vulvovaginal candidiasis, especially for patients who cannot use fluconazole, a common antifungal treatment.",
  "summary": null,
  "key_points": [
    "SCYNEXIS announces dual-pipeline strategy targeting ADPKD and invasive fungal infections",
    "Company invests in SCY-770 for ADPKD and SCY-247 for fungal infections, with BARDA funding",
    "SCY-770 in phase II study by end of 2024, SCY-247 completed phase I trials"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}